Graphen Brings on New SVP, Medical Innovation

By Susan Hu

Graphen, Inc. is thrilled to announce the appointment of Dr. Nathan Chen as its new Senior Vice President (SVP) of Medical Innovation. Dr. Chen's addition to the team is a significant milestone for the company, as he brings a wealth of expertise and experience to this crucial role.

Dr. Ching-Yung Lin, the Founder and CEO of Graphen, Inc., who is also a distinguished Fellow of IEEE and an Adjunct Professor at Columbia University, expressed his enthusiasm for Dr. Chen's arrival. He stated, "We are very fortunate to attract industry leader Dr. Chen to join and lead our growing team. His deep knowledge and extensive experience in the field will be instrumental in helping us develop valuable real-life applications and solidify our position as a leading AI company on the global stage."

Dr. Nathan Chen holds an impressive array of qualifications, including an M.D., Ph.D., MSc, and an MBA from insitutions around the world. His illustrious career has seen him in key leadership positions, such as Chief Medical Officer at Adimmune and Clinical Head at Pfizer, China and the Asia Region. His expertise spans a wide spectrum, encompassing drug development, medical business strategy, clinical development, regulatory affairs, and more.

Graphen is eager to leverage Dr. Chen's leadership in the medical innovation division. His role will be pivotal in harnessing the company's advanced AI technology for drug development and other AI-powered solutions. With Dr. Chen at the helm, Graphen, Inc. is poised to make significant strides in the field of medical innovation and continue its trajectory towards becoming a global leader in artificial intelligence applications.

Learn more about the latest AI technology and solutions at: https://graphen.ai/

If you want to learn more about AI, Graphen's technology, and how we can help you transform your business, please reach out to susanhu@graphen.ai.